PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
1280.26%
Cash & equivalents yoy growth at least 1.5x AXSM's 0.70%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Cash + STI yoy ≥ 1.5x AXSM's 0.70%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
≥ 1.5x AXSM's 8.49%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
≥ 1.5x AXSM's 7.23%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Exceeding 1.5x AXSM's 14.15%. Michael Burry suspects ballooning short-term obligations vs. competitor.
92.39%
Above 1.5x AXSM's 40.25%. Michael Burry sees a red flag for liquidity risk vs. competitor.
50.95%
Less than half of AXSM's -30.63%. David Dodd sees more deleveraging vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
50.95%
Less than half of AXSM's -25.02%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
54.32%
Above 1.5x AXSM's 4.28%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.21%
0.75-0.9x AXSM's -4.06%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.60%
Below half AXSM's 37.35%. Michael Burry sees potential underperformance in building shareholder capital.
1280.26%
≥ 1.5x AXSM's 7.23%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
50.95%
Above 1.5x AXSM's 2.81%. Michael Burry sees a major jump. Investigate leverage rationale.
22.84%
Above 1.5x AXSM's 4.12%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.